

Preclinical Research Collaborations in the Pharmaceutical Industry: <u>incentives and barriers</u>

Arsenio Nueda, Maribel Crespo Almirall Research

4 October 2018





Pharmaceutical Industry **Collaborations in the** Research reclinical

Index

- 1. <u>Introduction</u>: Is the Pharmaceutical industry interested in early Research?.
- 2. Examples of collaborations:
 - Public private partnerships.
 - AlmirallShare: Almirall Open Innovation Platform.
- 3. <u>Incentives and barriers</u> for external collaborations.

Introduction

Is the Pharmaceutical industry still interested in early research? Yes, of course.

Why?

- Early research implies INNOVATION.
- INNOVATION = Main driver for growth in the pharmaceutical industry.
- INNOVATION implies an IDEA that solves an UNMET NEED for PATIENTS.

How?

- Isolationism and closed innovation is history !!!.
- Collaborations and PARTNERSHIPS with KEY STAKE HOLDERS (Academia, Biotechs, Other Pharma, Funding Bodies) is essential for a successful business in research and to transform knowledge and innovative ideas into valuable solutions for patients.





Public-private partnerships with public funding

NANO DERM

- Almirall collaborates with ICMAB-CSIC and Leitat Technology Center in Nanomedicine applied to Dermatology.
- Nano4Derm will lead to the development of two types of nanocapsules containing active ingredients, Quatsomes and Polymeric Nanocapsules, aiming to address current unmet needs and challenges on topical treatment of Acne and Psoriasis.
- This project is funded by the Spanish Ministry of Science, Innovation and Universities through the modality Retos de Collaboración 2016, and co-financed by FEDER funds from the European Commission.



MULTI2HYCAT

- Almirall collaborates in MULTI2HYCAT, an EU project aimed to develop new multi-site organic-inorganic hybrid catalysts for multi-step chemical processes that will improve production of active ingredients.
- The MULTI2HYCAT consortium consists of 8 partners from 6 different European countries (Italy, Spain, UK, France, Belgium and Germany): 4 research centres (U. Piemonte Orientale, ITQ-CSIC, U. Southampton, and CNRS) and 4 companies (CAGE, Solvay, PNO and Almirall).
- This project is funded by the European Commission through Union's Horizon 2020 Research and Innovation program.





Open innovation platform: AlmirallShare


- AlmirallShare (<u>sharedinnovation.almirall.com</u>) is the Almirall Open Innovation platform created to facilitate collaborative projects and find innovative solutions in skin health.
- It is focused on R&D needs and challenges.




 Launched in 2017, AlmirallShare is the first crowdsourcing platform focused in Dermatology that offers a diversity of collaboration opportunities to the scientific community.



AlmirallShare calls 2017-2018



AlmirallShare results



Asia Europe North and South America Other

■ Asia ■ Europe ■ North and South America ■ Other

Evaluation process for new proposals ongoing 4 proposals selected for a new partnership 3 collaboration projects ready to start



Incentives and Barriers in Research Collaborations

INCENTIVES / BENEFITS	CHALLENGES / BARRIERS
 Opportunity to access disruptive innovation through public funding. 	 Balance between public programs rules vs internal business priorities.
 Capability and capacity expansion. Opportunity for cross-fertilization between partners: access to knowledge, expertise, different views. 	 Resources / logistics required to manage collaborations. Cost, which can be high in some business cases. Time to identify partner and set up agreement.
 Increased portfolio of programs/projects. Opportunity for early investment in innovative 	 Risk of dealing with new partners. Communication between different organizational
 Can focus internal efforts on high-value activities 	 or institutional cultures. Integration into internal processes.
 Risk-sharing and generation of potential revenues. 	 Alignment with internal objectives & expectations.



Some recommendations to manage challenges / barriers

CHALLENGES / BARRIERS

- Balance between public programs rules vs internal business priorities.
- Resources / logistics required to manage collaborations.
- Cost, which can be high in some business cases.
- Time to identify partner and set up agreement.
- Risk of dealing with new partners.
- Communication between different organizational or institutional cultures.
- Integration into internal processes.
- Alignment with internal objectives & expectations.

Recommendations

- Integrate partnerships as part of the routine company business model.
- Foster a relationship based on trust, respect and shared ownership.
- Due diligence on potential partners (run pilot studies when appropriate)
- Ensure involvement of company staff to minimize "not invented here" syndrome.
- Do not underestimate internal resources required to manage collaboration.
- Recognize and minimize risk of failure.

Overall, collaborations enrich our organizations, may have a high impact and can lead to long-term friendships.





Thank you